The UK government’s Biomedical Catalyst (BMC) programme has announced £23 million of funding for cutting edge health projects, including new software which enables radiologists to diagnose
The dwindling number of amyloid-targeting drugs in development for Alzheimer’s disease (AD) has been reduced by one more, after Biogen and Eisai pulled the plug on aducanumab.
UK biotech is booming, with the number of R&D companies increasing 65% since 2016 amid soaring annual investment of more than £2 billion, according to a new report.
